Mr. Stephen Kilmer reports

PROFOUND MEDICAL TO RELEASE SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 8 - CONFERENCE CALL TO FOLLOW

Profound Medical Corp. will release its second quarter 2024 financial results after the market close on Thursday, Aug. 8, 2024.

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

Second quarter 2024 results conference call details

Date:  Thursday, Aug. 8, 2024

Time:  4:30 p.m. ET

Live call registration:  Register on-line.

The call will also be broadcast live and archived on the company's website under webcasts in the investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing Tulsa-Pro, a technology that combines real-time MRI (magnetic resonance imaging), robotically driven transurethral ultrasound and closed-loop temperature feedback control. Tulsa-Pro is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. Tulsa-Pro has the potential to be a flexible technology in customizable prostate ablation, including intermediate-stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large-volume benign prostatic hyperplasia (BPH). Tulsa-Pro is CE (Conformite Europeenne) marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).

Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a humanitarian device exemption for the treatment of osteoid osteoma. The company is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.